The resistance of causative agents of sexually transmitted infections to azithromycin

Kashevarov D.F.; Kostolevskaya A.V.

doi:https://doi.org/10.17116/klinderma20181704113

Close metadata

Recommended articles:

Effectiveness of biological material self-collection in men for diagnosis of sexually transmitted infections. Russian Journal of Clinical Dermatology and Venereology. 2025;(6):790-797

Development of clinical models for the management of patients with sexually transmitted infections in order to optimize the delivery of specialized medical care to dermatovenereological patients. Russian Journal of Clinical Dermatology and Venereology. 2026;(2):151-160

Laboratory diagnosis of gonococcal infection. Modern aspects (literature review). Russian Journal of Clinical Dermatology and Venereology. 2026;(2):178-186

Modern approaches to the treatment of NCMT sexually transmitted infections (N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis). Part I. N. gonorrhoeae, C. trachomatis. Russian Journal of Clinical Dermatology and Venereology. 2026;(2):243-253

Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resistance and adaptation to a changing environment. Molecular Genetics, Microbiology and Virology. 2025;(2):3-13

Factors supporting chronic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

Management strategy for pregnant women with pelvic inflammatory disease and chronic chlamydia infection: the role of josamycin in the case of the replicated drug Jozaphen. Russian Bulletin of Obstetrician-Gynecologist. 2026;(1):94-100

Abstract:

In the first decade and a half of the 21th century, there was significant increase in the incidence and dissemination of sexually transmitted infections (STIs). The article presents an extensive evidence of the therapeutic efficacy of azithromycin in various STIs. Azithromycin is used to treat STIs in many countries around the world. Thus, in the USA and Australia, the drug is used to treat gonorrhea in combination with cephalosporins. Azithromycin is included in the European guidelines for the treatment of non-gonococcal urethritis. In recent years, there is increasingly more cases, where this drug was ineffective in the treatment of infections caused by Neisseria gonorrhoeae, Mycoplasma genitalium, and Chlamydia trachomatis. The time interval when azithromycin was used in this region, as well as the socioeconomic status of patients, can affect the development of resistance. So, while resistance to azithromycin increases in developed countries, the use of the drug in developing countries is not yet accompanied by development of resistance. The growth and spread of the resistance of STI agents to azithromycin necessitate further improvement of methods for rapid and reliable detection of resistance and development of new treatments.

Keywords:

azithromycin

resistance

sexually transmitted infections (STIs)

treatment effectiveness

Authors:

Kashevarov D.F.

FUV RNIMU im. N.I. Pirogova

Kostolevskaya A.V.

Moscow Scientic and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Close metadata

References:

Khamaganova IV, Khromova SS, Akhmedov KhB, Piven NP, Razakova RYu. Prevalence of mix Chlamydia-mycoplasma infection under the conditions of a megapolis. Rus j skin ven dis. 2009;2:57-58. (In Russ.)
Makhova TI, Anisimova NS, Goloveshkina EN, Kisina VI, Guschin AE. Prevalence of sexually transmitted infections and vaginal microbiocenosis disorders in asymptomatic patients. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya i venerologiya. 2016;6:37-41. (In Russ.) https://doi.org/10.17116/klinderma201615637-41
Khaldin AA. State-of-art of non-gonoccocal urethritis and prospects of their therapy. Rus j skin ven dis. 2004;3:42-45. (In Russ.)
Khamaganova IV, Kashevarov DF. Combined therapy of urogenital chlamidiasis. Vest Dermatol Venerol. 2005;5:62- 65. (In Russ.)
Gomberg MA. Relevant issue: chlamydia infection in obstetrics and gynecology. Med council.2013;8:66-68. (In Russ.)
Jiang FX, Lan Q, Le WJ, Su XH Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Hefei (2014â€”2015): genetic characteristics of antimicrobial resistance. BMC Infect Dis. 2017 May 25;17(1):366. https://doi.org/10.1186/s12879-017-2472-z
Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, Alm RA, Mueller JP, Rice PA. Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-623. https://doi.org/10.1128/AAC.01211-15
Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, Hook EW 3rd, Kubin G, Riedel S, Zenilman J, Pettus K, Sanders T, Sharpe S, Torrone E. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance â€” The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. MMWR Surveill Summ. 2016 Jul 15;65(7):1-19. https://doi.org/10.15585/mmwr.ss6507a1
Katz AR, Komeya AY, Kirkcaldy RD, Whelen AC, Soge OO, Papp JR, Kersh EN, Wasserman GM, O’Connor NP, O’Brien PS, Sato DT, Maningas EV, Kunimoto GY, Tomas JE. Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis. 2017 May 26. https://doi.org/10.1093/cid/cix485 [Epub ahead of print]
Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, O’Connor NP, O’Brien PS, Harauchi DH, Maningas EV, Soge OO, Kersh EN, Komeya A, Tomas JE, Wasserman GM, Kunimoto GY, Trees DL, Whelen AC. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA. Emerg Infect Dis. 2017 May;23(5):830-832. https://doi.org/10.3201/eid2305.170088
Kidd S, Workowski KA. Management of gonorrhea in adolescents and adults in the United States. Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S785-S801. https://doi.org/10.1093/cid/civ731
Lahra MM, Enriquez RP National Neisseria Network. Australian Gonococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2017 Mar 31;41(1):E.
Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, Whiley D. Treatment guidelines after an outbreak ofÂ azithromycin- resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis. 2017 Feb;17(2): 133-134. https://doi.org/10.1016/S1473-3099(17)30007-5
Bornstein M, Ahmed F, Barrow R, Risley JF, Simmons S, Workowski KA. Factors associated with primary care physician knowledge of the recommended regimen for treating gonorrhea. Sex Transm Dis. 2017 Jan;44(1): 13-16.
Bala M, Singh V, Bhargava A, Ramesh V. Trends of resistance to antimicrobials recommended currently and in the past for management of gonorrhea in the Apex STD center in India and comparison of antimicrobial resistance profile between 2002—2006 and 2007—2012. Sex Transm Dis. 2015 Apr; 42(4):218-222. https://doi.org/10.1097/OLQ.0000000000000261
Gose SO, Soge OO, Beebe JL, Nguyen D, Stoltey JE, Bauer HM. Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California. Sex Transm Dis. 2015 May;42(5):279-280. https://doi.org/10.1097/OLQ.0000000000000265
Trembizki E, Buckley C, Donovan B, Chen M, Guy R, Kaldor J, Lahra MM, Regan DG, Smith H, Ward J, Whiley DM. Direct real-time PCR-based detection of Neisseria gonorrhoeae 23S rRNA mutations associated with azithromycin resistance. J Antimicrob Chemother. 2015 Dec;70(12):3244-3249. https://doi.org/10.1093/jac/dkv274
Demczuk W, Sidhu S, Unemo M, Whiley DM, Allen VG, Dillon JR, Cole M, Seah C, Trembizki E, Trees DL, Kersh EN, Abrams AJ, de Vries HJC, van Dam AP, Medina I, Bharat A, Mulvey MR, Van Domselaar G, Martin I. Neisseria gonorrhoeae sequence typing for antimicrobial resistance, a novel antimicrobial resistance multilocus typing scheme for tracking global dissemination of N. gonorrhoeae strains. J Clin Microbiol. 2017 May;55(5):1454-1468. Epub 2017 Feb 22 https://doi.org/10.1128/JCM.00100-17
Johnson SR, Grad Y, Abrams AJ, Pettus K, Trees DL. Use of whole-genome sequencing data to analyze 23S rRNA-mediated azithromycinÂ resistance. Int J Antimicrob Agents. 2017 Feb;49(2):252-254. https://doi.org/10.1016/j.ijantimicag.2016.10.023
Mo X, Zhu C, Gan J, Wang C, Wei F, Gong W, Cai Q. Prevalence and correlates of Mycoplasma genitalium infection among prostatitis patients in Shanghai, China. Sex Health. 2016 Jul 4. [Epub ahead of print] https://doi.org/10.1071/SH15155
Li Y, Le WJ, Li S, Cao YP, Su XH. Metaanalysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int JSTD AIDS. 2017 Jan 1:956462416688562. [Epub ahead of print] https://doi.org/10.1177/0956462416688562
Horner PJ, Blee K, Falk L, van der Meijden W, Moi H. European guideline on the management of non-gonococcal urethritis. Int JSTD AIDS. 2016 Oct;27(11):928-937. https://doi.org/10.1177/0956462416648585
Horner P, Blee K, Oâ€™Mahony C, Muir P, Evans C, Radcliffe K, Clinical Effectiveness Group of the British Association for Sexual Health and HIV. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int JSTD AIDS. 2016 Feb;27(2):85-96. https://doi.org/10.1177/0956462415586675
Manhart LE, Jensen JS, Bradshaw CS, Golden MR, Martin DH. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S802-S817. https://doi.org/10.1093/cid/civ785
Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. Int JSTD AIDS. 2017 Feb;28(2): 127-132. https://doi.org/10.1177/0956462416630675
Lusk MJ, Garden FL, Cumming RG, Rawlinson WD, Naing ZW, Konecny P. Cervicitis: a prospective observational study of empiric azithromycin treatment in women with cervicitis and non-specific cervicitis. Int JSTD AIDS. 2017 Feb;28(2):120-126. https://doi.org/10.1177/0956462416628319
Dombrowski JC, Batteiger BE. Reconsidering the use of Azithromycin for Chlamydial urethritis. Sex Transm Dis. 2016 Oct;43(10):603-604. https://doi.org/10.1097/OLQ.0000000000000519
Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int JSTD AIDS. 2016 Dec;27(14):1303-1308.
Oâ€™Farrell N, Moi H. European guideline on donovanosis. Int JSTD AIDS. 2016 Jul;27(8):605-607. https://doi.org/10.1177/0956462416633626
Marks M, MitjÃ O, Vestergaard LS, Pillay A, Knauf S, Chen CY, Bassat Q, Martin DL, Fegan D, Taleo F, Kool J, Lukehart S, Emerson PM, Solomon AW, Ye T, Ballard RC, Mabey DC, Asiedu KB. Challenges and key research questions for yaws eradication. Lancet Infect Dis. 2015 Oct;15(10):1220-1225. https://doi.org/10.1016/S1473-3099(15)00136-X